Axis Spine received £830,000 (~USD $1.0 million) in new funding to bring products to the spine market, with an initial focus on the U.S. The investment will help Axis Spine launch a trial product in the U.S. after the ban on elective surgery is lifted.
Founder Jonathan Arcos said, “The current trading environment is of course very challenging, but this investment will take us to the next level. Thankfully we were at quite an advanced stage when the lockdown measures were first brought in and are delighted to have the funds in place to bring our first product onto the market.”
Axis Spine spent the past three years developing a range of implants. The company expects to secure FDA clearance for its first product in May. We note that at NASS 2019, the company debuted proprietary modular fusion cage technology designed to enable atraumatic insertion featuring in situ sizing with uncoupled height and lordosis and advanced in situ grafting capabilities.